N-Aryl-N-(1-L-4-piperidinyl)arylacetamides

A chemical compound selected from the group consisting of an N-aryl-N-(4-piperidinyl)arylacetamide having the formula ##STR106## and the pharmaceutically acceptable acid addition salts thereof, wherein:

• Ar is a member selected from the group consisting of pyridinyl and 2-pyrimidinyl;
• Ar.sup.1 is a member selected from the group consisting of phenyl, monoand di-substituted phenyl, wherein each substituent in said mono- and di-substituted phenyl is independently selected from the group consisting of halo, lower alkyl, hydroxy and lower alkyloxy;
• and
• X is a member selected from the group consisting of hydrogen, lower alkyloxycarbonyl and lower alkyloxymethyl.

A chemical compound selected from the group consisting of an N-aryl-N-(4-piperidinyl)arylacetamide having the formula:

• ##STR107## and the pharmaceutically acceptable acid addition salts thereof, wherein:
• Ar is a member selected from the group consisting of pyridinyl and 2-pyrimidinyl;
• Ar.sup.1 is a member selected from the group consisting of phenyl, monoand di-substituted and phenyl, wherein each substituent in said mono- and di-substituted phenyl is independently selected from the group consisting of halo, lower alkyl, hydroxy and lower alkyloxy;
• and
• X is a member selected from the group consisting of hydrogen, lower alkyloxycarbonyl and lower alkyloxymethyl.

A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective anti-arrhythmic amount of a chemical compound selected from the group consisting of an N-aryl-N-(4-piperidinyl)arylacetamide having the formula:

• ##STR108## and the pharmaceutically acceptable acid addition salts thereof, wherein:
• L is alkyl having from 1 to 10 carbon atoms;
• Ar is a member selected from the group consisting of pyridinyl and 2-pyrimidinyl;
• Ar.sup.1 is a member selected from the group consisting of phenyl, monoand di-substituted phenyl, wherein each substituent in said mono- and di-substituted phenyl is independently selected from the group consisting of halo, lower alkyl, hydroxy and lower alkyloxy;
• and
• X is a member selected from the group consisting of hydrogen, lower alkyloxycarbonyl and lower alkyloxymethyl.

A pharmaceutical composition comprising an orally ingestible pharmaceutical carrier and as an active ingredient an effective antiarrhythmic amount of a chemical compound selected from the group consisting of an N-aryl-N-(4-piperidinyl)arylacetamide having the formula:

• ##STR109## and the pharmaceutically acceptable acid addition salts thereof, wherein:
• Ar is a member selected from the group consisting of pyridinyl and 2-pyrimidinyl;
• Ar.sup.1 is a member selected from the group consisting of phenyl, monoand di-substituted phenyl, wherein each substituent in said mono- and di-substituted phenyl is independently selected from the group consisting of halo, lower alkyl, hydroxy and lower alkyloxy;
• and
• X is a member selected from the group consisting of hydrogen, lower alkyloxycarbonyl and lower alkyloxymethyl.

A pharmaceutical composition comprising an orally ingestible carrier and as an active ingredient an effective anti-arrhythmic amount of a chemical compound selected from the group consisting of an N-aryl-N-(4-piperidinyl)arylacetamide having the formula:

• ##STR110## and the pharmaceutically acceptable acid addition salts thereof, wherein:
• Ar is a member selected from the group consisting of pyridinyl and 2-pyrimidinyl;
• Ar.sup.1 is a member selected from the group consisting of phenyl, monoand di-substituted phenyl, wherein each substituent in said mono- and di-substituted phenyl is independently selected from the group consisting of halo, lower alkyl, hydroxy and lower alkyloxy;
• and
• X is a member selected from the group consisting of hydrogen, lower alkyloxycarbonyl and lower alkyloxymethyl.

A method of treating cardiac arrhythmia which comprises the systemic administration to warm-blooded animals of an effective anti-arrhythmic amount of a chemical compound selected from the group consisting of an N-aryl-N-(4-piperidinyl)arylacetamide having the formula:

• ##STR111## and the pharmaceutically acceptable acid addition salts thereof, wherein:
• L is alkyl having from 1 to 10 carbon atoms;
• Ar is a member selected from the group consisting of pyridinyl and 2-pyrimidinyl;
• Ar.sup.1 is a member selected from the group consisting of phenyl, monoand di-substituted phenyl, wherein each substituent in said mono- and di-substituted phenyl is independently selected from the group consisting of halo, lower alkyl, hydroxy and lower alkyloxy;
• and
• X is a member selected from the group consisting of hydrogen, lower alkyloxycarbonyl and lower alkyloxymethyl.